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ElderlyAbstract Background: Chronic kidney disease is independently associated with cardiovascular
disease (CVD) events in high-risk populations according to several studies. However, findings from
community-based population studies are insufficient. We studied the relationship between estimated
glomerular filtration rate (eGFR) and risk of coronary artery disease (CAD) events in patients
attending Zagazig University Hospital, Sharqiya governorate, Egypt.
Methods: A total of 800 subjects aged P60 years admitted to Internal Medicine Department or
attended medicine outpatient clinic were included in this study. Careful history and full clinical
examinations were done to assess the risk factors of CAD. Serum creatinine, lipid profile and serum
glucose were measured. Estimated eGFR was evaluated by creatinine based MDRD formula.
According to eGFR, patients were divided into 2 groups: group 1 with eGFRP 60 mL/min/1.73 m2
and Group 2 with eGFR< 60 mL/min/1.73 m (between 40 and 60 mL/min/1.73 m).
Results: 410 patients were found to have eGFRP 60 mL/min/1.73 m2, while 390 patients were
found to have eGFR< 60 mL/min/1.73 m2. eGFR was lower in patients with CAD (62
± 13 mL/min/1.73 m2) in comparison with patients without CAD (76 ± 11 mL/min/1.73 m2)
(P 6 0.001). Older age, hypertension, Diabetes and Low HDL are highly significant risk factors
for CAD in those patients (P 0.001).
Conclusions: Reduced eGFR is a significant risk factor for CAD events in older patients. Monitor-
ing of eGFR may have a pivotal role in early detection and management of CAD in those types of
patients.
 2016 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic kidney disease (CKD) is considered a public health
problem.1 Also, it is a disease entity including mild to end-
stage renal diseases due to any etiology.2 Serum creatinine is
generally thought to be a poor indicator of renal function. In
contrast, glomerular filtration rate (GFR) is a more accurate
measure of renal function.2 Cardiovascular disease (CVD) is
the main cause of mortality in chronic kidney disease patients.3x J Med
2 T.A. Ghonemy et al.Previous clinical trials have shown that reduced glomerular fil-
tration rate (GFR) is an independent risk factor for all-cause
mortality as well as adverse CVD events, such as myocardial
infarction and stroke,4,5 and patients with a low level of
GFR show increased exposure to CVD risk factors, such as
diabetes, hypertension and dyslipidemia.6,7
Many studies have been restricted to study patients with
estimated glomerular filtration rate (eGFR) below 60 mL/
min/1.73 m2 compared to above 60 mL/min/1.73 m.8–12
However the effects of earlier stages of renal function deterio-
ration on CAD outcomes have been less well studied particu-
larly in the elderly.13 Thus there is uncertainty as to whether
mild renal dysfunction may have adverse cardiovascular effects
independent of known risk factors in this population.
In the present study, we hypothesized that eGFR is related
to risk of CAD in the general population so we investigated the
relationship between reduced estimated GFR (eGFR) and risk
of CAD events, either stable or unstable ACS (Acute coronary
syndrome), in a community-based sample of elderly patients in
Zagazig University Hospital in the period between 2013 and
2015.
2. Methods
2.1. Patient selection
We collected 800 patients attending the outpatient clinic of our
hospital for follow-up of their comorbid diseases, during the
period from March 2013 to June 2015 to be included in this
prospective study.
Inclusion criteria: Patients were considered eligible for
enrollment if they were over 60 years of age. Patients were
divided into two groups according to eGFR: group 1 with
eGFRP 60 mL/min/1.73 m2 and group 2 with eGFR between
40 and 60 mL/min/1.73 m2 as shown in Table 1.
Exclusion criteria: Patients with malignant tumors, bedrid-
den status, mental disorder, and heart and lung failure and
patients with advanced chronic kidney disease were excluded
from the study before inclusion. An informed written consentTable 1 Baseline characteristics of all study population.
Patient Characteristics eGFRP 60
(n= 410)
(Group 1)
eGFR (40–60) n=
(390) (Group 2)
Age 66 ± 6 69 ± 5
Gender M/F 200/210 341/49
Basal disease
Angina pectoris
(n= 223)
110 113
Old myocardial
infarction (n= 168)
77 91
Ischemic cardiopathy
(n= 70)
29 41
No CAD (n= 339) 194 145
Risk factor
Hypertension 127 176
Diabetes mellitus 41 51
Dyslipidemia 180 203
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study protocol. The study protocol was reviewed and
approved by our Local Institutional Human Research Ethical
Committee as it conforms to the ethical guidelines of the 1975
Declaration of Helsinki, as revised in 2002.
2.2. Clinical and laboratory assessment
Using a pretested questionnaire, information was collected on
demographic data, family history of premature CAD, medical
history of CAD, drug history, and smoking status. Weight was
measured with patients minimally clothed without shoes using
digital scales. Height was measured in the standing position
without shoes using tape meter while shoulders were in normal
alignment. Waist circumference (WC) was measured at the
umbilical level and that of the hip at the maximum level over
light clothing using an un-stretched tape meter without any
pressure to body surface, and BMI was calculated as weight
(kg) divided by square of the height (m2). After a 15-min rest
in the sitting position, two measurements of BP were taken
on the right arm using a standardized mercury sphygmo-
manometer and the mean of the two measurements was con-
sidered the participant’s BP. A blood sample was drawn
between 7 AM and 9 AM from all study participants after
12–14 h of overnight fasting. All the blood samples were sent
to the laboratory on the day of blood collection. Plasma glu-
cose was measured using an enzymatic colorimetric method
with glucose oxidase. Fasting plasma glucose (FPG) measure-
ment was performed for all participants and the standard 2-h
post-challenge plasma glucose (2-h PCPG) test for those not
taking glucose-lowering drugs. Total cholesterol (TC) was
assayed using the enzymatic colorimetric method with choles-
terol esterase and cholesterol oxidase. High-density lipoprotein
cholesterol (HDL-C) was measured after precipitation of
apolipoprotein B-containing lipoproteins with phospho-
tungstic acid. Triglycerides were assayed using enzymatic col-
orimetric assay with glycerol phosphate oxidase. Serum
creatinine (Cr) levels were assayed by kinetic colorimetric Jaffe
method. The sensitivity of the assay was 0.2 mg/dL (range, 18–
1330 mmol/L [0.2–15 mg/dL]). GFR was estimated using the
Quadratic GFR equation proposed by Rule and colleagues.14
The estimated GFR calculated in mL/min/1.73 m2 using the
revised ‘‘175” Modification of Diet in Renal Disease (MDRD)
study equation was: 175 (standardized serum creatinine (Scr)
in mg/dL)1.154  (Age)0.203  0.742 with creatinine values
entered in mg/dL into the equation.15
According to the eGFR, we classified our patients into two
groups: group 1 with eGFRP 60 mL/min and group 2 with
eGFR< 60 mL/min/1.73 m2 (range between 40 and 60 mL/
min).
2.3. Diagnosis of coronary artery disease
For the diagnosis of CAD events, we depended on the
American Heart Association classification for cardiovascular
events16–18 in addition to pre-tested questionnaire, full medical
history and full medical examination. Coronary heart disease
(CHD) includes cases of definite myocardial infarction diag-
nosed by electrocardiography (ECG) and biomarkers (creatine
phosphokinase-MB, lactate dehydrogenase, troponin), proba-
ble myocardial infarction (positive ECG findings plus cardiacte as a predictor of coronary artery disease events in elderly patients, Alex J Med
Table 3 Comparison of those with and without CAD.
All
participants
n= 800
CAD
n= 461
No CAD
n= 339
P value
Age 65 ± 9 69 ± 2 65 ± 4 <0.001
Hypertension 303 (37.8%) 212
(70%)
91 (30%) <0.001
eGFR 75.2 ± 14 62 ± 13 76 ± 11 <0.001
Glomerular filtration rate and coronary artery disease 3symptoms or signs and biomarkers showing negative or equiv-
ocal results), and unstable angina pectoris (new cardiac symp-
toms or changing symptom patterns and positive ECG
findings with normal biomarkers).
2.4. Statistical analysis
All quantitative data are presented as mean ± standard devi-
ation (x ± s), and all categorical data are presented as percent-
ages. The differences of these variables among different groups
(eGFR> 60, 40–60 mL/min/1.73 m2) were examined using
chi-square statistics for categorical variables and one-way
analysis of variance for continuous values. The differences of
these variables were compared between subjects with group 1
and group 2 by Student’s t-test for continuous variables. All
data entry and management were performed on Excel spread-
sheet and then were analyzed by the SPSS statistical package,
version 15.0 (SPSS Inc., http://www.SPSS.com). A P-
value < 0.05 was considered statistically significant and highly
significant if P< 0.001.
3. Results
A total of 800 patients were included in our analysis, there
were 541 male (67.6%) and 259 female (32.4%) patients, and
the age ranged from 60 to 74 years with an average of 65
± 9 years. 92 patients (11.5%) were diabetic and 303
(37.8%) were hypertensive. According the presence or absence
of CAD, patients were classified as angina pectoris (n= 223),
old myocardial infarction (n= 168), Ischemic cardiomyopa-
thy (n= 70), and patients without significant CAD
(n= 339). Table 2 shows a comparison of laboratory, clinical
and demographic characteristics in both groups according to
the eGFR. There was a significant relationship between both
groups according to age, presence of CAD, diabetes and
hypertension (P< 0.001). Table 3 shows a significant relation-
ship between patients with and without CAD in relation to
eGFR (P< 0.001). Also there was a significant relationship
between both groups according to age and hypertension.
Table 4 shows a relation of risk factors in the two eGFR
groups. In males the relation of diabetes, hypertension, ele-
vated LDL-C and decreased HDL-C was significantly differentTable 2 Laboratory, clinical and demographic characteristics
in both groups according to eGFR.
Group 1
(eGFRP 60)
Group 2 (eGFR
40–60)
P value
Age 66 ± 7 69 ± 5 <0.001
Male 200 (48.8%) 341 (87.4%) 0.08
CAD patients 215 (52.4%) 259 (66%) <0.001
Dyslipidemia 180 (44%) 203 (52%) 0.42
Diabetes 41 (10%) 51 (13%) <0.001
Hypertension 127 (31%) 176 (45%) <0.001
BMI (kg/m2) 25.5 ± 3.8 25.8 ± 3.5 0.15
TG (mg/dL) 150 ± 99 145 ± 85 0.52
LDL cholesterol
(mg/dL)
101 ± 22 98 ± 25 0.08
HDL cholesterol
(mg/dL)
48 ± 12 45 ± 11 <0.001
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high in mild renal function group but overweight and high TG
were not significantly different in the two eGFR groups. In
female patients, the proportion of diabetes, hypertension,
overweight, elevated LDL-C and decreased HDL-C was signif-
icantly different in the two eGFR groups and the proportion
of risk factors increased with the decreasing of the level of
eGFR.
4. Discussion
In the present study, we have found that prevalence of CAD
events in elderly patients with eGFR between 40 and 60 mL/
min is more than in population with eGFR> 60 mL/min
and also that there was more deterioration of eGFR with
increase in age. Renal impairment is considered a major limit-
ing factor for long-term prognosis in CAD patients.19,20 The
risk of death associated with renal dysfunction increases as
eGFR declines in previous data in the general population.21,22
Impaired renal function may increase cardiovascular risk in
many ways as renal dysfunction is related to other diseases
such as diabetes mellitus and hypertension that themselves
have a poorer outcome. In addition to that, renal dysfunction
in association with these factors has a markedly worse progno-
sis. The association between CKD and cardiovascular disease
varied based on different cardiovascular risk factor combina-
tions and was highest in those with diabetes.23 Renal dysfunc-
tion might have its harmful effect via pathways independent of
other traditional risk factors related to increased CAD risk.22
A decreasing GFR is also related to several other factors
that affect outcome in cardiac diseases such as impaired left
ventricular systolic function and more severe symptoms of
heart failure.24
This study was designed to explain the clinical significance
of eGFR-defined CKD as a predictor of secondary outcomes
of CAD. As a result, the eGFR-defined CKD was an indepen-
dent risk factor for secondary events in patients with CAD.
Regarding a pathophysiological link between CAD and
CKD in our results, the increased inflammation and oxidative
stress, which have an important role in the pathophysiology of
CAD progression, could be associated with poorer renal func-
tion. In addition, renal dysfunction may be associated with
multiple other physiological changes, including high levels of
hypercalcemia, hyperuricemia, homocysteine, anemia, and
uremia, all of which have detrimental cardiovascular effects.25
A previous epidemiological study indicated that CKD patients
typically had elevated TG and reduced HDL-C, but no
significant alterations in TC and LDL-C.26 In our study no
independent relation was found between BMI and mild renalte as a predictor of coronary artery disease events in elderly patients, Alex J Med
Table 4 Relation of risk factors with eGFR levels (mL/min/1.73 m2) in males and females.
Variable Male (eGFR(mL/min/1.73 m2)) Female (eGFR(mL/min/1.73 m2))
P60 (n= 200) 40–60 (n= 341) P value P60 (n= 210) 40–60 (n= 49) P value
Diabetes 19 (9.5%) 41 (12%) <0.001 22 (10.47%) 10 (20.4%) <0.001
Hypertension 90 (45%) 167 (48.9%) 0.32 37 (17.6%) 9 (18.4%) 0.21
BMIP 25 (kg/m2) 100 (50%) 177 (51.9%) 0.51 131 (62.3%) 32 (65.3%) <0.05
TGP 197.2 (mg/dL) 120 (60%) 219 (64.2%) 0.01 123 (58.5%) 30 (61.2%) 0.02
LDL cholesterolP 130.3 (mg/dL) 30 (15%) 72 (21.1%) <0.001 42 (20%) 12 (24.4%) <0.001
HDL< 40.2 (mg/dL) 33 (16.5%) 77 (22.5%) <0.001 21 (10%) 8 (16.3) <0.001
4 T.A. Ghonemy et al.impairment. This may be due to the fact that only morbid obe-
sity (defined as BMIP 35 kg/m2) was related to CKD27 while
there were only 21 individuals who had BMIP 35 kg/m2 in
our study. Also, in this study, elevated LDL-C was shown as
an independent risk factor with CKD and reduced renal func-
tion. Therefore, lipid-lowering therapy appears to be an impor-
tant part of CKD management. Certainly, patients with end-
stage renal failure have greatly accelerated vascular disease
and a high cardiac risk.28 Thus, kidney function integrates
the effects of many factors affecting cardiovascular outcome.
Also it has been suggested that, given the effects of vascular
disease on kidney function, it may serve as an essential indica-
tor of vascular health.29 Although the mechanism behind the
relation between impaired renal function and the risk of
CAD events is not completely understood, several mechanisms
have been proposed. Traditional CAD risk factors, such as
older age, smoking, hypertension, and dyslipidemia, often
coexist with CKD30–32 and the positive association of these
factors with incident CAD is well proved.33,34 Elevated asym-
metric dimethyl arginine, reduced nitric oxide bioavailability,
and endothelial dysfunction in kidney disease, which are asso-
ciated with atherosclerosis, are also defined as factors linking
impaired kidney function and the risk of incident CAD.35,38
In addition, inflammatory markers such as C-reactive protein,
fibrinogen, interleukin-6, tumor necrosis factor a, factor VIIc,
factor VIIIc, plasmin–antiplasmin complex, D-dimer, the
adhesion molecules E-selection, vascular cell adhesion mole-
cule 1, and Intercellular Adhesion Molecule 1 are often
elevated. Also, the activation of the renin–angiotensin system,
which may depend on the adaptation to loss of renal mass that
results in changes in renal hemodynamics, frequently occurs in
CKD. These factors may alter the progression of atherosclero-
sis through their share to the production of reactive oxygen
species.36,37 In addition, increased promoters of calcification
and reduced inhibitors of calcification may be responsible for
the linkage between kidney impairment and CAD risk.35,38
As to eGFR, factors including activation of the renin–
angiotensin system, anemia, elevated asymmetric dimethyl
arginine, and hyperhomocysteinemia could represent a link
between reduced eGFR and increased CAD risk.36,37
Our result may reflect the magnitude of the association
between kidney function and the risk of incident CAD because
kidney function may change over time, potentially affecting
their relation with coming CAD events.39
The main strengths of our study are its community-based
population in Sharqiya governorate, Egypt, and large sample
size. The main study limitations are as follows: (1) renal
impairment was defined based on a single measurement. The
measurements of kidney damage were made just once, and
the definition of CKD needs persistence of kidney damagePlease cite this article in press as: Ghonemy TA et al. Reduced glomerular filtration ra
(2016), http://dx.doi.org/10.1016/j.ajme.2016.06.006for at least 3 months,40 which means that, in order to define
CKD, indicators of renal impairment should be re-evaluated
at least once after 3 months. The single measurement of indica-
tors of CKD in the present study might overestimate the
prevalence of CKD. (2) We did not use multivariate analysis
to get the different predictors with their odds ratio and confi-
dence interval.
5. Conclusion
We found that reduction of eGFR appears to be a strong pre-
dictor as a risk factor for CAD events in our elderly patients. It
is possibly related to age-related structural changes in older
kidneys due to a reduction in functioning glomeruli. Monitor-
ing of eGFR may have a pivotal role in early detection and
management of CAD in those types of patients.
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